Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

WSK V102

Next Previous
Drug Profile

WSK V102

Alternative Names: WSK-V102

Latest Information Update: 28 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Westvac Biopharma
  • Class COVID-19 vaccines; Synthetic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported COVID 2019 infections

Most Recent Events

  • 28 Apr 2026 No recent reports of development identified for phase-I development in COVID-2019-infections(Prevention) in China (IM)
  • 01 Mar 2023 Westvac Biopharma plans a phase I trial in COVID-2019 infection (Prevention) in March 2023 (IM) (NCT05765604)
  • 26 Aug 2021 Westvac Biopharma announces intention to submit NDA for Unspecified indication (Prevention) in China in Q3 2022

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top